Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co., Ltd.
Qurient Co., Ltd.
Amgen
Fujian Medical University Union Hospital
Immunitas Therapeutics
Cancer Research UK
University Hospital, Antwerp
Royal Marsden NHS Foundation Trust
Cybrexa Therapeutics
NextCure, Inc.
NGM Biopharmaceuticals, Inc
Oslo University Hospital